Experian drops after Deutsche Bank cuts target, FY27 growth risks linger

Experian drops after Deutsche Bank cuts target, FY27 growth risks linger

June 10, 2026

London, June 10, 2026, 16:02 BST

  • Experian was off around 1.8% in late London trading. Morningstar had the stock at 2,572p at 15:46 BST, down from the last close of 2,619p.
  • Deutsche Bank has cut its price target on the stock but kept its buy rating, MT Newswires reported, citing MarketScreener.
  • Experian holds to a 6% to 8% organic growth target for FY27, and investors are watching for more color when the company gives its next trading update on July 16.

Experian PLC shares fell on Wednesday after Deutsche Bank cut its price target for the credit data group, though the broker kept its buy rating. That added more pressure on the stock, which is still coming off last month’s drop. Shares slid after Experian’s guidance pointed to slower organic growth for FY27.

Experian shares traded at 2,572p in late London trade, off 47p, or 1.79%, at 15:46 BST. The stock swung between 2,515p and 2,640p in a choppy session.

Experian shares have underperformed the broader UK market this year. Morningstar puts the credit-checking firm’s one-year total return at minus 28.69% as of June 9, while the FTSE 100 total return index gained 19.55%. That 48-point gap is why even small broker moves are drawing notice.

Deutsche Bank kept its buy rating on Experian, but cut its price target. MarketScreener ran an MT Newswires headline at 08:35 a.m. EDT: “Deutsche Bank Cuts Experian PT, Affirms Buy Rating.” The consensus page still showed a mean buy from 18 analysts. MarketScreener

Experian reported June 9 that CEO Brian Cassin and CFO Lloyd Pitchford picked up shares after their 2023 awards vested. Both sold part of those shares to pay tax and social security, the company said. Cassin and Pitchford together got 254,413 shares and sold 103,326 to cover taxes, keeping the rest.

Guidance is the main concern. On May 20, Experian reported FY26 ongoing revenue of $8.43 billion, up 13% at actual rates, with benchmark EBIT up 15% to $2.41 billion. CEO Brian Cassin described it as “a record year” and said the company is taking a “prudent approach” to macro risks connected to the Middle East. Experian plc

Investors looked ahead, not at last year, as Experian guided for FY27 total revenue growth of 8%-11% and organic revenue up 6%-8%. Organic growth removes the impact of currency shifts and M&A. Reuters said that range is just under analysts’ 6.3%-9.8% forecast from a company poll.

Experian shares are under pressure. The company’s analyst-estimates page showed the FY27 organic revenue growth consensus at 8.0%, right at the upper end of management’s target and not above it. That’s left some investors disappointed, since the shares had traded on expectations of higher growth. For them, management’s “good enough” guidance hasn’t cleared the bar. Experian plc

Experian’s North America unit posted 10% organic growth for FY26, its best region. Latin America grew 8%. The UK and Ireland came in at 2%, but second-half growth picked up. Organic revenue in B2B rose 8%, lifted by demand in alternative data, mortgage, fraud prevention and analytics.

AI is still in the mix on valuation. Experian said AI boosted coding productivity 10% to 15% in FY26, according to Reuters. JPMorgan analyst Jane Sparrow said management was “on the front foot” about the benefits of AI as investors raised questions about risks to its data-analysis operations. Reuters

Macro caution and tech jitters could hit Experian at once. Lenders might slow credit-card and loan activity if rates stay high or Middle East volatility ramps up. AI could also pressure fees, making data work cheaper and cutting what investors pay for Experian’s earnings. Cash flow helps steady things: Experian posted $2.2 billion in benchmark operating cash, with a 93% conversion rate, and set a new $1 billion buyback through June 30, 2027.

The next real check comes July 16 with the first-quarter FY27 trading update. Investors want to see if that 6% to 8% organic growth range is just being conservative, or if weaker credit demand, client caution, or maybe AI worries are beginning to take hold.

Stock Market Today

  • Haleon Shares Rise Slightly on £175 Million India Expansion and Buyback
    June 10, 2026, 11:25 AM EDT. Haleon shares edged up 0.18% to 336.20p on June 10, as investors focused on the company's £175 million investment in a new oral-health manufacturing plant in India. The expansion targets growth in Madhya Pradesh with plans to serve over 300 million consumers and expand rural distribution, aiming at a £23 billion consumer health market by 2030. Haleon also announced buybacks totaling 16.6 million shares, supporting the share price amid recent declines. First-quarter revenue grew 2.2% organically, led by an 8.3% jump in Oral Health brands like Sensodyne, despite a 3.4% drop in Respiratory Health sales due to a mild cold and flu season. The India investment signals a strategic pivot toward long-term growth in emerging markets.